Semaglutide
Semaglutide is a medication that mimics a natural hormone your body already makes called GLP-1. It was originally created to help people with type 2 diabetes control their blood sugar, but it became famous for something else: helping people lose weight. The medication comes as a weekly injection, and it's so effective that it's transformed how doctors think about weight management and metabolic health.
Here's how it works inside you. When you inject semaglutide, it travels through your bloodstream and attaches to special receptor sites in three key places: your pancreas, your gut, and your brain. In your pancreas, it tells your body to release insulin in response to food while also shutting down glucagon, a hormone that raises blood sugar. This keeps your glucose levels stable without causing dangerous crashes.
But the weight loss magic happens in your brain. Semaglutide essentially turns down your appetite dial. It hits areas in your hypothalamus and brainstem that control hunger and fullness, making you naturally want to eat less. It also slows how fast your stomach empties after meals, so you feel satisfied longer. Think of it as your body's natural "I'm full" signal getting turned up to normal levels. Because semaglutide has a fatty acid attached to it, your body holds onto it for about a week, which is why one injection does the work for seven days.
Dosage Information
Typical Dose
0.25-2.4 mg weekly (weight management), 0.5-2 mg weekly (diabetes)
Frequency
Once weekly
Administration
Subcutaneous injection or oral tablet (Rybelsus)
Half-Life
7 days
Notes
Always titrated gradually over 16-20 weeks to minimize GI side effects. Requires medical supervision. Oral bioavailability is approximately 1% — injectable form is far more efficient.
Why this matters
Week-long half-life enables once-weekly dosing; steady state reached after 4–5 weeks.
Protocol cycle
Dose Calculator
Calculate your draw amount for an insulin syringe (U-100)
Draw to the
10
unit mark
Draw 10 units for your 250mcg dose of Semaglutide
This calculator is for educational purposes. Always verify your calculations and consult a healthcare professional.
Where does Semaglutide sit?
See how this peptide compares across all 150 peptides in our database.
Evidence Score
0.68
Compound Data
Molecular Formula
C187H291N45O59
Molecular Weight
4114.00 g/mol
IUPAC Name
18-[[(1R)-4-[2-[2-[2-[2-[2-[2-[[(5S)-5-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3R)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-amino-3-(1H-imidazol-5-yl)propanoyl]amino]-2-methylpropanoyl]amino]-4-carboxybutanoyl]amino]acetyl]amino]-3-hydroxybutanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-4-carboxybutanoyl]amino]acetyl]amino]-5-oxopentanoyl]amino]propanoyl]amino]propanoyl]amino]-6-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-carbamimidamido-1-[[2-[[(2S)-5-carbamimidamido-1-(carboxymethylamino)-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-6-oxohexyl]amino]-2-oxoethoxy]ethoxy]ethylamino]-2-oxoethoxy]ethoxy]ethylamino]-1-carboxy-4-oxobutyl]amino]-18-oxooctadecanoic acid
PubChem CID
56843331Potential Side Effects
Semaglutide discussions
Quick Facts
- Administration
- Subcutaneous injection or oral tablet (Rybelsus)
- Typical Dose
- 0.25-2.4 mg weekly (weight management), 0.5-2 mg weekly (diabetes)
- Frequency
- Once weekly
- References
- 0 curated + 39 from PubMed
- Clinical Trials
- 49 registered
- Evidence Score
- 0.7 / 100
Frequently Asked Questions about Semaglutide
What is Semaglutide?
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist originally developed for type 2 diabetes management and approved by the FDA under the brand names Ozempic (injectable) and Rybelsus (oral). It later received approval as Wegovy for chronic weight management, making it one of the most clinically significant peptides of the last decade. Semaglutide has an extraordinary clinical evidence base with multiple large-scale Phase 3 trials demonstrating substantial weight loss, cardiovascular risk reduction, and glycemic control. It represents the forefront of metabolic peptide therapeutics.
How does Semaglutide work?
Semaglutide is a long-acting GLP-1 receptor agonist with 94% homology to human GLP-1. It works by binding to GLP-1 receptors in the pancreas, brain, and gastrointestinal tract. In the pancreas it stimulates glucose-dependent insulin secretion and suppresses glucagon release, improving glycemic control without causing hypoglycemia at normal glucose levels. In the hypothalamus and brainstem it reduces appetite and food intake by modulating hunger and satiety signaling circuits. It slows gastric emptying, increasing feelings of fullness after meals. The addition of a C18 fatty acid chain via a linker gives semaglutide an extended half-life of approximately one week, enabling once-weekly dosing. Cardiovascular benefits appear to result from direct GLP-1 receptor effects on the heart and vasculature.
What is the recommended dosage for Semaglutide?
The typical dose is 0.25-2.4 mg weekly (weight management), 0.5-2 mg weekly (diabetes). Once weekly. Administration: Subcutaneous injection or oral tablet (Rybelsus). Always titrated gradually over 16-20 weeks to minimize GI side effects. Requires medical supervision. Oral bioavailability is approximately 1% — injectable form is far more efficient.
What are the side effects of Semaglutide?
Nausea (very common, especially during dose escalation). Vomiting (common). Diarrhea (common). Constipation (common). Reduced appetite (intended effect, can be pronounced). Injection site reactions (uncommon). Risk of thyroid C-cell tumors (black box warning — avoid in personal or family history of MTC). Pancreatitis (rare but serious)
What is the Semaglutide cycle protocol?
Semaglutide is typically cycled ongoing. Gradual titration over 16-20 weeks initially
Questions reflect common community inquiries. This is not medical advice.